TY - JOUR TI - Time-resolved phosphoproteomics reveals scaffolding and catalysis-responsive patterns of SHP2-dependent signaling AU - Vemulapalli, Vidyasiri AU - Chylek, Lily A AU - Erickson, Alison AU - Pfeiffer, Anamarija AU - Gabriel, Khal-Hentz AU - LaRochelle, Jonathan AU - Subramanian, Kartik AU - Cao, Ruili AU - Stegmaier, Kimberley AU - Mohseni, Morvarid AU - LaMarche, Matthew J AU - Acker, Michael G AU - Sorger, Peter K AU - Gygi, Steven P AU - Blacklow, Stephen C A2 - Cooper, Jonathan A A2 - Mayer, Bruce J VL - 10 PY - 2021 DA - 2021/03/23 SP - e64251 C1 - eLife 2021;10:e64251 DO - 10.7554/eLife.64251 UR - https://doi.org/10.7554/eLife.64251 AB - SHP2 is a protein tyrosine phosphatase that normally potentiates intracellular signaling by growth factors, antigen receptors, and some cytokines, yet is frequently mutated in human cancer. Here, we examine the role of SHP2 in the responses of breast cancer cells to EGF by monitoring phosphoproteome dynamics when SHP2 is allosterically inhibited by SHP099. The dynamics of phosphotyrosine abundance at more than 400 tyrosine residues reveal six distinct response signatures following SHP099 treatment and washout. Remarkably, in addition to newly identified substrate sites on proteins such as occludin, ARHGAP35, and PLCĪ³2, another class of sites shows reduced phosphotyrosine abundance upon SHP2 inhibition. Sites of decreased phospho-abundance are enriched on proteins with two nearby phosphotyrosine residues, which can be directly protected from dephosphorylation by the paired SH2 domains of SHP2 itself. These findings highlight the distinct roles of the scaffolding and catalytic activities of SHP2 in effecting a transmembrane signaling response. KW - signal transduction KW - mass spectrometry KW - PTPN11 KW - epidermal growth factor receptor KW - phosphatase JF - eLife SN - 2050-084X PB - eLife Sciences Publications, Ltd ER -